Learning Objective
By the end of this section, the learner should be able to:
- Explain the role of β-blockers in reducing myocardial oxygen demand in stable angina
- Differentiate their effects in stable versus vasospastic angina
- Describe the pharmacologic basis for the use of carvedilol in chronic angina management
Role of β-Blockers in Stable (Effort) Angina
β-blockers are primarily used in:
👉 Stable angina (angina of effort)
They improve myocardial oxygen balance by:
- Decreasing heart rate
- Reducing myocardial contractility
- Lowering cardiac output
This leads to:
- ✔️ Reduced myocardial oxygen demand
- ✔️ Increased diastolic perfusion time
Contraindication in Vasospastic (Prinzmetal) Angina
β-blockers are:
❌ Contraindicated in vasospastic angina
Because:
- Blocking β₂-mediated vasodilation leaves:
- Unopposed α-adrenergic coronary vasoconstriction
This may:
- 👉 Worsen coronary vasospasm
- 👉 Exacerbate ischemia
Carvedilol in Angina of Effort
Carvedilol is a:
👉 Non-selective β-blocker with additional α₁-blocking activity
Pharmacologic Effects
| Effect | Clinical Outcome |
|---|---|
| β₁ blockade | ↓ HR and contractility |
| β₂ blockade | ↓ Sympathetic stimulation |
| α₁ blockade | Peripheral vasodilation |
This results in:
- ✔️ Reduced afterload
- ✔️ Reduced myocardial oxygen demand
Clinical Relevance
Carvedilol is:
👉 Clinically comparable to isosorbide in the management of:
- ✔️ Chronic stable (effort) angina
making it an effective alternative in long-term therapy.
